Aethlon director granted 21,815 AEMD shares

Aethlon Medical Inc. director Nicolas Gikakis received a stock-based compensation award in the form of 21,815 shares of common stock on April 17, 2026.

Rhea-AI Filing Summary

Aethlon Medical Inc. director Nicolas Gikakis received a stock-based compensation award in the form of 21,815 shares of common stock on April 17, 2026. The award is structured as restricted stock units that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, conditioned on his continued service with the company. Following this grant, he directly holds 22,844 shares of Aethlon Medical common stock. This filing reflects a compensation-related acquisition rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 21,815 shares

Grant/Award 1 txn

Insider Gikakis Nicolas

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	21,815	$2.29	$50K

Holdings After Transaction: Common Stock — 22,844 shares (Direct)

Footnotes (1)

1. F1. The Reporting Person was granted RSUs that vest in four equal quarterly installments on each of June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, subject to the Reporting Person's continued service with the Company on each such vesting date.

Key Figures

RSU grant size: 21,815 shares Grant reference price: $2.29 per share Shares held after grant: 22,844 shares +2 more

5 metrics

RSU grant size 21,815 shares Common stock award on April 17, 2026

Grant reference price $2.29 per share Transaction price per share for RSU grant

Shares held after grant 22,844 shares Total direct AEMD holdings following transaction

Vesting dates 4 installments June 30, 2026; Sept 30, 2026; Dec 31, 2026; Mar 31, 2027

Transaction code A Grant, award, or other acquisition of common stock

Key Terms

RSUs, vest, transaction code "A", restricted stock units

4 terms

RSUs financial

"The Reporting Person was granted RSUs that vest in four equal quarterly installments"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vest financial

"RSUs that vest in four equal quarterly installments on each of June 30, 2026"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

transaction code "A" regulatory

"transaction_code": "A" ... "transaction_code_description": "Grant, award, or other acquisition""

restricted stock units financial

"was granted RSUs that vest in four equal quarterly installments"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aethlon Medical (AEMD) disclose for Nicolas Gikakis?

Aethlon Medical disclosed that director Nicolas Gikakis received a grant of 21,815 shares of common stock as a stock-based compensation award. The award is documented on a Form 4 insider filing and represents a non-market, compensation-related acquisition of shares.

How many AEMD shares does Nicolas Gikakis hold after this Form 4 transaction?

After the reported grant, Nicolas Gikakis directly holds 22,844 shares of Aethlon Medical common stock. This total includes the newly awarded shares and provides a snapshot of his direct equity position following the April 17, 2026 compensation transaction.

Is the AEMD Form 4 transaction an open-market purchase or a compensation grant?

The Aethlon Medical Form 4 shows a compensation grant, not an open-market purchase. The transaction code "A" and description indicate a grant, award, or other acquisition, with shares delivered as restricted stock units rather than bought on the open market.

What is the vesting schedule for Nicolas Gikakis’ AEMD RSU award?

The RSU award to Nicolas Gikakis vests in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027. Vesting is expressly conditioned on his continued service with Aethlon Medical on each vesting date.

At what reference price was the AEMD RSU grant to Nicolas Gikakis recorded?

The Form 4 records the 21,815-share award at a reference value of $2.29 per share. This figure appears as the transaction price per share associated with the grant, reflecting how the compensation value is measured for reporting purposes rather than an open-market trade price.

Does the AEMD Form 4 show any derivative or option exercises by Nicolas Gikakis?

No derivative or option exercises are shown for Nicolas Gikakis in this Form 4. The filing reports only a non-derivative common stock award, and the derivative position summary is empty, indicating no options, warrants, or other derivatives were exercised or reported in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gikakis Nicolas

(Last) (First) (Middle)

11555 SORRENTO VALLEY RD, STE 203

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AETHLON MEDICAL INC [ AEMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/17/2026		A		21,815(1)	A	$2.29	22,844	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted RSUs that vest in four equal quarterly installments on each of June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, subject to the Reporting Person's continued service with the Company on each such vesting date.

	/s/ Nicolas Gikakis, by: James B. Frakes, Attorney-in-fact	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)